Article Information
History
- March 22, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Ella A. Eklund1,2,3,
- Mathilda Orgard1,2,
- Delice Wallin1,2,
- Sama I. Sayin3,
- Henrik Fagman4,5,
- Sukanya Raghavan6,
- Levent M Akyürek4,5,
- Jan Nyman3,7,
- Clotilde Wiel1,
- Andreas Hallqvist3,7 and
- Volkan I. Sayin1,2,*
- 1Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Center for Cancer Research, University of Gothenburg, Gothenburg, Sweden
- 2Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden
- 3Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden
- 4Department of Laboratory Medicine, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden
- 5Department of Clinical Pathology, Sahlgrenska University Hospital, Gothenburg, Sweden
- 6Department of Microbiology and Immunology, Institute for Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
- 7Department of Oncology, Institute of Clinical Sciences, University of Gothenburg, Gothenburg, Sweden
- ↵*Correspondence to: V.I.S volkan.sayin{at}wlab.gu.se
Posted March 22, 2024.
Equalizing prognostic disparities in stage III KRAS-mutant NSCLC: addition of durvalumab to combined chemoradiotherapy improves survival
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos